Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Methodology|Interests|Funding|Corrections
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Trial register facet

Trial records in heart failure with preserved ejection fraction and obesity

16 records bearing on heart failure with preserved ejection fraction and obesity.

Showing 0 records on this page

Records

16 documents

Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.

RecordCompoundPhaseStatusDesignRandomisedYearCertainty
STEP-HFpEF-DMSemaglutidePhase 3ReportedRandomised, double-blind, placebo-controlled6162024Moderate
SUMMITTirzepatidePhase 3ReportedRandomised, double-blind, placebo-controlled7312024Moderate
STEP-HFpEF-DM-BODY-COMPprogramme recordSemaglutidePhase 3ReportedRandomised, double-blind, placebo-controlled—2024Very low
SUMMIT-BIOMARKERprogramme recordTirzepatidePhase 3ReportedRandomised, double-blind, placebo-controlled—2024Very low
SUMMIT-ADHERENCEprogramme recordTirzepatidePhase 3ReportedObservational—2024Very low
SUMMIT-OLEprogramme recordTirzepatidePhase 3ReportedSingle-arm open-label—2024Very low
SUMMIT-ELDERLYprogramme recordTirzepatidePhase 3ReportedRandomised, double-blind, placebo-controlled—2024Very low
SUMMIT-REGIONAL-JPprogramme recordTirzepatidePhase 3ReportedRandomised, double-blind, placebo-controlled—2024Very low
STEP-HFpEFSemaglutidePhase 3ReportedRandomised, double-blind, placebo-controlled5292023Moderate
STEP-HFpEF-HEPATIC-IMPprogramme recordSemaglutidePhase 1ReportedPhase 1 ascending dose—2023Very low
STEP-HFpEF-DDIprogramme recordSemaglutidePhase 1ReportedRandomised crossover—2023Very low
ELAM-PH2-HFPEFSS-31 (elamipretide)Phase 2ReportedRandomised, double-blind, placebo-controlled712019Low
ELAM-PH2-HFPEF-ADHERENCEprogramme recordSS-31 (elamipretide)Phase 2ReportedObservational—2019Very low
ELAM-PH2-HFPEF-BIOMARKERprogramme recordSS-31 (elamipretide)Phase 2ReportedRandomised, double-blind, placebo-controlled—2019Very low
ELAM-PH2-HFPEF-ELDERLYprogramme recordSS-31 (elamipretide)Phase 2ReportedRandomised, double-blind, placebo-controlled—2019Very low
ELAM-PH2-HFPEF-OLEprogramme recordSS-31 (elamipretide)Phase 2ReportedSingle-arm open-label—2019Very low
Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.